Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200036/S012

eCoin Peripheral Neurostimulator

BOSTON SCIENTIFIC CORPORATION · Decision date Sep 9, 2026

MEDTECHLEDGER EXPLANATIONP200036/S012

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-09 for the eCoin Peripheral Neurostimulator under application P200036/S012, submitted by Boston Scientific Corporation. The supplement falls under the process change category covering manufacturer, sterilizer, packager or supplier, and the recorded statement describes a change in the frequency of setting the bioburden recovery efficiency.

The device category is an implantable electrical tibial stimulator for urinary incontinence, listed under product code QPT with specialties in gastroenterology and urology. This action concerns that specific manufacturing process change within the existing application rather than a new approval of the whole system. The source record includes no supporting documents, so the technical detail of the revised bioburden recovery procedure and any FDA review basis remain unknown.

Whether the changed bioburden recovery frequency affects sterilization assurance or clinical performance cannot be determined from the available fields, and no such conclusion is drawn here.

FDA approval order statement

a change in the frequency of setting the bioburden recovery efficiency
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200036/S012
Regulatory pathway
PMA supplement
Product code
QPT
Decision code
OK30
Decision date
Sep 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.

Product code
QPT
FDA device class
3

For the original device and its historical approval scope, see PMA P200036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200036 · Original PMA

    eCoin Peripheral Neurostimulator

  2. P200036/S012 received

    Application receipt date recorded by FDA.

  3. P200036/S012 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P200036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200036

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalMar 1, 2022FDA

Explore the linked device profile

Other records with product code QPT

Product / regulatory recordCompanyPathwayDecision dateSource
AltavivaP240011/S016
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
Medtronic NeuromodulationPMA approvalSep 18, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
100 Boston Scientific Way, Marlborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records